Grail Inc (GRAL)
NASDAQ:GRAL
Want to see GRAL full AI Analyst Report?
GRAL Stock Chart & Stats
$51.71
-$1.19(-6.66%)
At close: 4:00 PM EST
$51.71
-$1.19(-6.66%)
Day’s Range― - ―
52-Week Range$29.95 - $118.84
Previous CloseN/A
Volume371.20K
Average Volume (3M)782.51K
Market Cap
$2.74B
Enterprise Value$2.53B
Total Cash (Recent Filing)$823.11M
Total Debt (Recent Filing)$51.03M
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Aug 18, 2026EPS Estimate
-2.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.37
Shares Outstanding42,916,590
10 Day Avg. Volume664,493
30 Day Avg. Volume782,511
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.22
Price to Sales (P/S)21.37
P/FCF Ratio-10.52
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue16.23
Enterprise Value/Gross Profit-109.64
Enterprise Value/Ebitda-7.50
Forecast
1Y Price Target
$65.57Price Target Upside26.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-10.35
Revenue Forecast (FY)$179.56M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetVery low leverage and a sizable cash balance give the company multi-quarter to multi-year runway to execute commercialization, invest in evidence generation and expand the salesforce. This structural financial flexibility reduces near-term refinancing risk and supports strategic optionality.
Robust Volume And Revenue GrowthSustained test-volume growth and rising screening revenue indicate expanding clinical adoption and demand. Higher volumes enable fixed-cost leverage and better unit economics, supporting a durable path toward improved gross margins as integrations and provider adoption scale over months.
Regulatory And Evidence ProgressPMA acceptance and an extensive evidence base materially improve the company's pathway to formal market authorization and payer conversations. Large trial datasets and ASCO readouts enhance credibility with clinicians and payers, a structural enabler for broader coverage and long-term adoption.
Bears Say
Negative Gross Profit & Deep LossesPersistently negative gross profit and very large net losses indicate the core unit economics are not yet sustainable. Without durable margin improvement, the business will need ongoing capital to scale, and eventual profitability remains uncertain absent better pricing, mix or cost reductions.
Continued Cash Burn And Negative Free Cash FlowSignificant negative operating and free cash flow reflect ongoing investment-heavy commercialization. Even with a strong cash balance today, sustained cash burn narrows strategic options, raises the probability of future equity raises and dilution, and constrains discretionary spending when scaling.
Clinical Result And Reimbursement UncertaintyA primary endpoint miss in a large population study creates persistent questions about clinical utility and complicates guideline inclusion and payer coverage decisions. This structural credibility gap can slow provider adoption and delay CMS/insurer reimbursement, impairing long-term scale.
GRAIL Inc News
GRAL FAQ
What was Grail Inc’s price range in the past 12 months?
Grail Inc lowest stock price was $29.95 and its highest was $118.84 in the past 12 months.
What is Grail Inc’s market cap?
Grail Inc’s market cap is $2.74B.
When is Grail Inc’s upcoming earnings report date?
Grail Inc’s upcoming earnings report date is Aug 18, 2026 which is in 58 days.
How were Grail Inc’s earnings last quarter?
Grail Inc released its earnings results on May 05, 2026. The company reported -$2.29 earnings per share for the quarter, beating the consensus estimate of -$2.763 by $0.473.
Is Grail Inc overvalued?
According to Wall Street analysts Grail Inc’s price is currently Undervalued.
Does Grail Inc pay dividends?
Grail Inc does not currently pay dividends.
What is Grail Inc’s EPS estimate?
Grail Inc’s EPS estimate is -2.65.
How many shares outstanding does Grail Inc have?
Grail Inc has 42,916,590 shares outstanding.
What happened to Grail Inc’s price movement after its last earnings report?
Grail Inc reported an EPS of -$2.29 in its last earnings report, beating expectations of -$2.763. Following the earnings report the stock price went up 15.349%.
Which hedge fund is a major shareholder of Grail Inc?
Currently, no hedge funds are holding shares in GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$65.57 (26.81% Upside)
$65.57 (26.81% Upside)
Blogger Sentiment
Bullish
GRAL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 6.8%
Last 30 Days ▼ 6.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
31.58%
12-Months-Change
Fundamentals
Return on Equity
-16.42%
Trailing 12-Months
Asset Growth
-1.55%
Trailing 12-Months
Company Description
Grail Inc
GRAIL, Inc. is a biotechnology firm dedicated to advancing innovations for detecting cancer at its earliest stages. Among its key offerings is Galleri, a screening test designed for individuals aged 50 and above who show no symptoms of the disease. GRAIL also offers DAC (Diagnostic Aid for Cancer), which assists in expediting the diagnostic process for patients where cancer is clinically suspected. Additionally, the company is actively engaged in the development of minimal residual disease (MRD) tests and various other post-diagnosis solutions. Established in 2015 with its headquarters in Menlo Park, California, GRAIL, Inc. previously operated as a subsidiary of Illumina, Inc.
GRAL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful clinical and regulatory progress: test volumes grew 50% YoY, screening revenue rose 37% YoY, adjusted gross profit improved 38% YoY, PMA was accepted, and large trial datasets and upcoming ASCO readouts support the evidence base. At the same time, the NHS-Galleri primary combined endpoint was not met, ASP pressure and continued operating losses persist, media scrutiny and competitive activity create near-term headwinds, and regulatory/timing uncertainties (including possible FDA AdCom and CMS coverage) remain. Overall, positives around volume growth, margins improvement, cash runway, partnerships and regulatory progress outweigh the challenges, but the company still faces execution and perception risks that will need to be addressed in coming quarters.View all GRAL earnings summariesGRAL Stock 12 Month Forecast
Average Price Target
$65.57
▲(26.81% Upside)
Technical Analysis
Ownership Overview
19.26% Insiders
12.45% Mutual Funds
40.87% Other Institutional Investors
13.99% Public Companies and Individual Investors